Abstract
Cellular senescence is the state of permanent inhibition of cell proliferation. Senescent cells are characterized by several features including increased activity of senescence-associated β-galactosidase (SA-β-GAL) and senescenceassociated secretory phenotype (SASP). In vitro, 2 types of senescence have been described. One is telomere-dependent replicative senescence and the second is stress-induced premature senescence (SIPS). Despite some tissue-specific characteristics many kinds of cells, including stem/progenitor cells, can undergo senescence both in vitro and in vivo. Senescent cells were detected in murine, primate and human tissues using different markers. There is mounting evidence that senescent cells contribute to ageing and age-related disease by generating a low grade inflammation state (senescenceassociated secretory phenotype-SASP). Even though cellular senescence is a barrier for cancer it can, paradoxically, stimulate development of cancer via proinflammatory cytokines. There is evidence that senescent vascular cells, both endothelial and smooth muscle cells, participate in atherosclerosis and senescent preadipocytes and adipocytes have been shown to lead to insulin resistance. Thus, modulation of cellular senescence is considered as a potential pro-longevity strategy. This can be achieved by: elimination of selected senescent cells, epigenetic reprogramming of senescent cells, preventing cellular senescence or influencing the secretory phenotype. Some pharmacological interventions have already shown promising results.
Keywords: Age-related disease, biomarkers, DNA damage, low-grade inflammation, secretory phenotype, senescence, telomeres.
Current Vascular Pharmacology
Title:Cellular Senescence in Ageing, Age-Related Disease and Longevity
Volume: 12 Issue: 5
Author(s): Ewa Sikora, Anna Bielak-Zmijewska and Grazyna Mosieniak
Affiliation:
Keywords: Age-related disease, biomarkers, DNA damage, low-grade inflammation, secretory phenotype, senescence, telomeres.
Abstract: Cellular senescence is the state of permanent inhibition of cell proliferation. Senescent cells are characterized by several features including increased activity of senescence-associated β-galactosidase (SA-β-GAL) and senescenceassociated secretory phenotype (SASP). In vitro, 2 types of senescence have been described. One is telomere-dependent replicative senescence and the second is stress-induced premature senescence (SIPS). Despite some tissue-specific characteristics many kinds of cells, including stem/progenitor cells, can undergo senescence both in vitro and in vivo. Senescent cells were detected in murine, primate and human tissues using different markers. There is mounting evidence that senescent cells contribute to ageing and age-related disease by generating a low grade inflammation state (senescenceassociated secretory phenotype-SASP). Even though cellular senescence is a barrier for cancer it can, paradoxically, stimulate development of cancer via proinflammatory cytokines. There is evidence that senescent vascular cells, both endothelial and smooth muscle cells, participate in atherosclerosis and senescent preadipocytes and adipocytes have been shown to lead to insulin resistance. Thus, modulation of cellular senescence is considered as a potential pro-longevity strategy. This can be achieved by: elimination of selected senescent cells, epigenetic reprogramming of senescent cells, preventing cellular senescence or influencing the secretory phenotype. Some pharmacological interventions have already shown promising results.
Export Options
About this article
Cite this article as:
Sikora Ewa, Bielak-Zmijewska Anna and Mosieniak Grazyna, Cellular Senescence in Ageing, Age-Related Disease and Longevity, Current Vascular Pharmacology 2014; 12 (5) . https://dx.doi.org/10.2174/1570161111666131219094045
DOI https://dx.doi.org/10.2174/1570161111666131219094045 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Imaging in Thromboembolic Risk Stratification for Atrial Fibrillation: Recent Patents and Current Practice
Recent Patents on Medical Imaging Prematurely Aged Children: Molecular Alterations Leading to Hutchinson-Gilford Progeria and Werner Syndromes
Current Aging Science Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design Anti-inflammatory Effects of Dietary Antioxidants
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Progress in the Rational Design for Polypharmacology Drug
Current Pharmaceutical Design The Effects of Current Therapies on Airway Remodeling in Asthma and New Possibilities for Treatment and Prevention
Current Molecular Pharmacology Meet Our Editorial Board Member
Current Drug Targets Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design The Effect of Counseling on Breastfeeding Self-Efficacy (BSFE) in Women with Gestational Diabetes
Current Women`s Health Reviews Immunomodulation in Polytrauma and Polymicrobial Sepsis - Where Do We Stand?
Recent Patents on Inflammation & Allergy Drug Discovery Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Synthesis and Biological Activities of Some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide Derivatives
Letters in Drug Design & Discovery Therapeutic Potential of microRNA Against Th2-associated Immune Disorders
Current Topics in Medicinal Chemistry Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets The Role of Fibrate Treatment in Dyslipidemia: An Overview
Current Pharmaceutical Design